Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 12, Issue 6, Pages 1332-1342
Publisher
Informa UK Limited
Online
2015-11-21
DOI
10.1080/21645515.2015.1108500
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France
- (2015) Didier Riethmuller et al. BMC PUBLIC HEALTH
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial
- (2015) Dan Apter et al. Clinical and Vaccine Immunology
- Hypothesis: Human papillomavirus vaccination syndrome—small fiber neuropathy and dysautonomia could be its underlying pathogenesis
- (2015) Manuel Martínez-Lavín CLINICAL RHEUMATOLOGY
- Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
- (2015) Mélanie Drolet et al. LANCET INFECTIOUS DISEASES
- Present status of human papillomavirus vaccine development and implementation
- (2015) Rolando Herrero et al. LANCET ONCOLOGY
- Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging
- (2015) Douglas R Lowy et al. LANCET ONCOLOGY
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
- (2015) Elmar A. Joura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy
- (2015) Miriam Nakalembe et al. Infectious Agents and Cancer
- National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014
- (2015) Sarah Reagan-Steiner et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries
- (2015) D Scott LaMontagne et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- HPV Type Attribution in High-Grade Cervical Lesions: Assessing the Potential Benefits of Vaccines in a Population-Based Evaluation in the United States
- (2014) S. Hariri et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Update on Vaccination Clinical Trials for HPV-Related Disease
- (2014) Britt K. Erickson et al. CLINICAL THERAPEUTICS
- Peripheral Sympathetic Nerve Dysfunction in Adolescent Japanese Girls Following Immunization with the Human Papillomavirus Vaccine
- (2014) Tomomi Kinoshita et al. INTERNAL MEDICINE
- Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women
- (2014) B. Baldur-Felskov et al. JNCI-Journal of the National Cancer Institute
- Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
- (2014) Sepehr N Tabrizi et al. LANCET INFECTIOUS DISEASES
- Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia–Grade 2
- (2014) Philip E. Castle et al. OBSTETRICS AND GYNECOLOGY
- No Adverse Signals Observed After Exposure to Human Papillomavirus Type 6/11/16/18 Vaccine During Pregnancy
- (2014) Mary Ann Goss et al. OBSTETRICS AND GYNECOLOGY
- Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine
- (2014) Paulo S Naud et al. Human Vaccines & Immunotherapeutics
- Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study
- (2014) Mark Jit et al. Lancet Global Health
- Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment
- (2013) A. C. Rodriguez et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Towards the eradication of HPV infection through universal specific vaccination
- (2013) Piergiorgio Crosignani et al. BMC PUBLIC HEALTH
- Declining Rates of High-Grade Cervical Lesions in Young Women in Connecticut, 2008-2011
- (2013) L. M. Niccolai et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Safety of Human Papillomavirus Vaccines: A Review
- (2013) Kristine K. Macartney et al. DRUG SAFETY
- Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection
- (2013) Asia Asiaf et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Postural tachycardia syndrome following human papillomavirus vaccination
- (2013) S. Blitshteyn EUROPEAN JOURNAL OF NEUROLOGY
- Achieving high and equitable coverage of adolescent HPV vaccine in Scotland
- (2013) Katy Sinka et al. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
- Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010
- (2013) Lauri E. Markowitz et al. JOURNAL OF INFECTIOUS DISEASES
- Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects
- (2013) L. Grimaldi-Bensouda et al. JOURNAL OF INTERNAL MEDICINE
- Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels
- (2013) Ahmedin Jemal et al. JNCI-Journal of the National Cancer Institute
- Clinical trials of human papillomavirus vaccines and beyond
- (2013) Matti Lehtinen et al. Nature Reviews Clinical Oncology
- Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England
- (2013) D. Mesher et al. VACCINE
- Infrastructure Requirements for Human Papillomavirus Vaccination and Cervical Cancer Screening in Sub-Saharan Africa
- (2013) Rengaswamy Sankaranarayanan et al. VACCINE
- Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study
- (2013) L. Arnheim-Dahlstrom et al. BMJ-British Medical Journal
- Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme
- (2012) Agnes Binagwaho et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Contributions of Recent and Past Sexual Partnerships on Incident Human Papillomavirus Detection: Acquisition and Reactivation in Older Women
- (2012) A. F. Rositch et al. CANCER RESEARCH
- Cervical Cancer Screening, Diagnosis and Treatment Interventions for Racial and Ethnic Minorities: A Systematic Review
- (2012) Susan B. Glick et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Fall in Human Papillomavirus Prevalence Following a National Vaccination Program
- (2012) S. N. Tabrizi et al. JOURNAL OF INFECTIOUS DISEASES
- A Cohort Effect of the Sexual Revolution May Be Masking an Increase in Human Papillomavirus Detection at Menopause in the United States
- (2012) Patti E. Gravitt et al. JOURNAL OF INFECTIOUS DISEASES
- The Challenge of Follow-Up in a Low-Income Colposcopy Clinic
- (2012) Dana M. Chase et al. Journal of Lower Genital Tract Disease
- Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis
- (2012) Nicolas Van de Velde et al. JNCI-Journal of the National Cancer Institute
- Cervical Cancer Trends in the United States: A 35-Year Population-Based Analysis
- (2012) Olusola Adegoke et al. JOURNAL OF WOMENS HEALTH
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
- (2012) Talía Malagón et al. LANCET INFECTIOUS DISEASES
- Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
- (2012) Catherine de Martel et al. LANCET ONCOLOGY
- Human Papillomavirus Vaccine Introduction – The First Five Years
- (2012) Lauri E. Markowitz et al. VACCINE
- Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study
- (2012) P. Oakeshott et al. BMJ-British Medical Journal
- Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine
- (2011) C. Chao et al. JOURNAL OF INTERNAL MEDICINE
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study
- (2011) Julia ML Brotherton et al. LANCET
- Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial
- (2011) Aimée R Kreimer et al. LANCET ONCOLOGY
- Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink
- (2011) Julianne Gee et al. VACCINE
- Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials
- (2010) Dominique Descamps et al. Human vaccines & immunotherapeutics
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
- (2010) Mark H. Einstein et al. Human vaccines & immunotherapeutics
- Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
- (2010) Nubia Muñoz et al. JNCI-Journal of the National Cancer Institute
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- (2010) Silvia de Sanjose et al. LANCET ONCOLOGY
- Rate of and Risks for Regression of Cervical Intraepithelial Neoplasia 2 in Adolescents and Young Women
- (2010) Anna-Barbara Moscicki et al. OBSTETRICS AND GYNECOLOGY
- Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
- (2009) Barbara A. Slade JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years
- (2009) Cosette M. Wheeler et al. JOURNAL OF INFECTIOUS DISEASES
- The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
- (2009) Darron R. Brown et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
- (2009) J Paavonen et al. LANCET
- Infection with Human Papillomavirus and HIV among Young Women in Kampala, Uganda
- (2008) Cecily Banura et al. JOURNAL OF INFECTIOUS DISEASES
- Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study
- (2008) Margaret RE McCredie et al. LANCET ONCOLOGY
- Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities, and Cancer
- (2008) Cosette Marie Wheeler OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA
- Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
- (2008) Thomas Verstraeten et al. VACCINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started